Drugs / ORT247
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06769620 | Jun 2022 → Oct 2023 | amyotrophic lateral sclerosis | Orthogonal Neuroscience Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORT247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06769620 ↗ |
| Route | Intravenous | “escalating intravenous doses of ORT247” NCT06769620 ↗ |